Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cortexyme Inc
(NQ:
CRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 29, 2022
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cortexyme Inc
< Previous
1
2
Next >
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022
July 27, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588
July 27, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Announces Preclinical Data Demonstrating Efficacy of COR803 for the Treatment of Coronavirus Infections
June 21, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Appoints June Bray to its Board of Directors
June 13, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Appoints Dr. Philip Low to Its Board of Directors
May 20, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Successfully Completes Acquisition of Novosteo
May 20, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme to Participate at 4th International Conference on Porphyromonas gingivalis and Related Species in Oral and Systemic Diseases
May 12, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Announces Agreement to Acquire Novosteo
May 10, 2022
From
Cortexyme, Inc.
Via
Business Wire
NASDAQ:CRTX Investor Alert: Investigation over Potential Wrongdoing at Cortexyme, Inc.
April 29, 2022
San Diego, CA -- (SBWIRE) -- 04/29/2022 -- Certain directors of Cortexyme, Inc. are under investigation over potential breaches of fiduciary duties.
Via
SBWire
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Cortexyme, Inc. Investors With Losses to Inquire About Securities Class Action Investigation – CRTX
April 05, 2022
From
The Rosen Law Firm, P.A.
Via
Business Wire
Cortexyme Provides New GAIN Trial Data at AD/PD 2022 Demonstrating Potential Benefit of Lysine Gingipain Inhibition in Mild to Moderate Alzheimer’s Population
March 21, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Appoints Marwan Sabbagh, MD, to its Board of Directors
March 15, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme to Present New GAIN Trial Data at AD/PD 2022
March 14, 2022
From
Cortexyme, Inc.
Via
Business Wire
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm
February 24, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
NASDAQ:CRTX Shareholder Notice: Investigation over Potential Securities Laws Violations by Cortexyme, Inc.
February 24, 2022
San Diego, CA -- (SBWIRE) -- 02/24/2022 -- Cortexyme, Inc. is under investigation over potential securities laws violations in connection with certain financial statements.
Via
SBWire
CORTEXYME ALERT: Bragar Eagel & Squire, P.C. Is Investigating Cortexyme, Inc. on Behalf of Cortexyme Stockholders and Encourages Investors to Contact the Firm
February 23, 2022
From
Bragar Eagel & Squire
Via
Business Wire
Investigation Notice: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
February 18, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Investigation Alert: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
February 17, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
February 16, 2022
Los Angeles - (NewMediaWire) - February 16, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Cortexyme,...
Via
NewMediaWire
INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
February 15, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Cortexyme, Inc. with Losses of $100,000 to Contact the Firm
February 14, 2022
From
The Schall Law Firm
Via
Business Wire
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Cortexyme, Inc. Investors with Losses in Excess of $100K to Inquire About Securities Class Action Investigation – CRTX
February 14, 2022
From
Rosen Law Firm
Via
Business Wire
Cortexyme Announces Pipeline Update and Anticipated 2022 Milestones
February 01, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Announces Change in Executive Leadership Team
February 01, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application
January 26, 2022
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
November 23, 2021
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants With Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
November 11, 2021
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
November 04, 2021
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
October 26, 2021
From
Cortexyme, Inc.
Via
Business Wire
Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021
September 27, 2021
From
Cortexyme, Inc.
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.